EGFR and non-small cell lung carcinoma: As observed in the clinic and in a study comparing icotinib with gefitinib in previously treated patients with advanced NSCLC [23], the EGFR exon 19 deletion was associated with a better response to treatment compared to the EGFR p.L858R mutation.